Literature DB >> 12032782

Dysregulation of apoptosis genes in hematopoietic malignancies.

Shinichi Kitada1, Irene M Pedersen, Aaron D Schimmer, John C Reed.   

Abstract

Ever since the discovery of Bcl-2 and the elucidation of its role in apoptosis, tremendous interest has arisen in prospects for triggering suicide of malignant cells by exploiting knowledge emerging from apoptosis research. In this review, we summarize information about the multiple genetic lesions which have been identified in apoptosis-regulatory genes of hematopoietic and lymphoid neoplasms. Emerging data about the structural and biochemical details of apoptosis proteins and their upstream regulators have reveal novel strategies for therapeutic intervention, some of which are under interrogation in clinical trials currently.

Entities:  

Mesh：

Year:  2002        PMID： 12032782     DOI： 10.1038/sj.onc.1205327

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  41 in total

1.  Functional genomics of tumor suppressor miR-196b in T-cell acute lymphoblastic leukemia.

Authors:  Suman Bhatia; Deepak Kaul; Neelam Varma
Journal:  Mol Cell Biochem       Date:  2010-10-06       Impact factor: 3.396

Review 2.  Insights into the mitochondrial signaling pathway: what lessons for chemotherapy?

Authors:  Catherine Brenner; Morgane Le Bras; Guido Kroemer
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

3.  Prognostic impact of bim, puma, and noxa expression in human colon carcinomas.

Authors:  Frank A Sinicrope; Rafaela L Rego; Kenji Okumura; Nathan R Foster; Michael J O'Connell; Daniel J Sargent; Harold E Windschitl
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

4.  Cellular stress responses: cell survival and cell death.

Authors:  Simone Fulda; Adrienne M Gorman; Osamu Hori; Afshin Samali
Journal:  Int J Cell Biol       Date:  2010-02-21

5.  Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.

Authors:  Andrew W Roberts; Ranjana H Advani; Brad S Kahl; Daniel Persky; John W Sweetenham; Dennis A Carney; Jianning Yang; Todd B Busman; Sari H Enschede; Roderick A Humerickhouse; John F Seymour
Journal:  Br J Haematol       Date:  2015-05-05       Impact factor: 6.998

6.  Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.

Authors:  Daniel A Luedtke; Yongwei Su; Jun Ma; Xinyu Li; Steven A Buck; Holly Edwards; Lisa Polin; Juiwanna Kushner; Sijana H Dzinic; Kathryn White; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-02-26

7.  Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.

Authors:  Aksana K Jones; Kevin J Freise; Suresh K Agarwal; Rod A Humerickhouse; Shekman L Wong; Ahmed Hamed Salem
Journal:  AAPS J       Date:  2016-05-27       Impact factor: 4.009

8.  Bcl-2 overexpression enhances tumor-specific T-cell survival.

Authors:  Jehad Charo; Steven E Finkelstein; Navrose Grewal; Nicholas P Restifo; Paul F Robbins; Steven A Rosenberg
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

9.  Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis.

Authors:  Karin Hartmann; Metin Artuc; Stephan E Baldus; Thomas K Zirbes; Barbara Hermes; Juergen Thiele; Yoseph A Mekori; Beate M Henz
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 10.  Targeting the apoptosis pathway in hematologic malignancies.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2014-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.